NGNE

Neurogene Inc

27.01

Nov 02 • 8:03 AM ET -0.54 (-1.96%)

Healthcare Biotechnology USA Small NASD

Peers: TSHA ACAD RGNX LXEO QURE ABEO SLDB VYGR KRYS PASG

| Held by: VTI IWM XBI VXF IWN IBB FESM VTWO IWC VHT

Index	RUT
Market Cap	540.50M
Enterprise Value	323.46M
Income	-111.11M
Sales	0.00M
Book/sh	13.72
Cash/sh	11.26
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	131
IPO	Mar 07, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.97
P/C	2.40
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.63
Current Ratio	10.63
Debt/Eq	0.04
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-5.50
EPS next Y	-5.23
EPS next Q	-1.36
EPS this Y	-32.92%
EPS next Y	7.28%
EPS next 5Y	-3.15%
EPS past 3/5Y	0.52% -45.84%
Sales past 3/5Y	- -
EPS Y/Y TTM	-18.84%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-46.26%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-7.50% -

Insider Own	16.27%
Insider Trans	-0.59%
Inst Own	86.73%
Inst Trans	12.03%
ROA	-41.02%
ROE	-45.32%
ROIC	-49.95%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.46%
SMA50	-11.45%
SMA200	-3.06%
Trades

Shs Outstand	20.01M
Shs Float	16.76M
Short Float	30.39%
Short Ratio	17.49
Short Interest	5.09M
52W High	43.66 -38.14%
52W Low	15.93 69.55%
Volatility	12.96% 9.73%
ATR (14)	2.36
RSI (14)	49.45
Beta	1.76
Rel Volume	0.01
Avg Volume	291.23K
Volume	75

Perf Week	14.74%
Perf Month	5.30%
Perf Quarter	-21.51%
Perf Half Y	-4.29%
Perf YTD	31.12%
Perf Year	-21.16%
Perf 3Y	98.60%
Perf 5Y	-81.65%
Perf 10Y	-87.00%
Recom	1.00
Target Price	77.00
Prev Close	27.55
Price	27.01
Change %	-1.96%

Consensus

Strong Buy

Avg. Price Target

$77.00

Implied Upside

+185.1%

Analysts10incl. previous ratings

Rating Distribution9 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 08, 2026	Initiated	JJP Morgan	Overweight	$60	+122.1%
Jun 03, 2026	Initiated	RRodman & Renshaw	Buy	$70	+159.2%
Jun 17, 2025	Initiated	CCraig Hallum	Buy	$50	+85.1%
May 16, 2025	Downgrade	RRobert W. Baird	Outperform → Neutral	$24	-11.1%
Jun 27, 2024	Initiated	BBMO Capital Markets	Outperform	$65	+140.7%
Jun 11, 2024	Initiated	RRobert W. Baird	Outperform	$54	+99.9%
Apr 29, 2024	Initiated	LLeerink Partners	Outperform	$46	+70.3%
Mar 21, 2024	Initiated	WWilliam Blair	Outperform	$61	+125.8%
Jan 08, 2024	Initiated	HH.C. Wainwright	Buy	$45	+66.6%
Jan 05, 2024	Initiated	SStifel	Buy	$31	+14.8%
Jan 04, 2024	Initiated	TTD Cowen	Outperform

Oct-27-26 07:30AM	Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome (Business Wire) +14.66%
Oct-20-26 07:30AM	Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress (Business Wire) +5.09%
Oct-05-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-26 07:30AM	Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
Sep-04-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:36AM	Loading…
Aug-11-26 07:36AM	Neurogene: Q2 Earnings Snapshot (Associated Press)
07:30AM	Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates (Business Wire)
Aug-04-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-06-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.87% +13.02%
Jul-01-26 07:00AM	Neurogene Inc. Announces Pricing of $125 Million Public Offering (Business Wire) +7.73%
Jun-30-26 04:01PM	Neurogene Inc. Announces Proposed Public Offering (Business Wire)
Jun-29-26 07:00AM	Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Jun-08-26 07:30AM	Neurogene Announces Successful Completion of Dosing in Embolden Registrational Trial of NGN-401 for Rett Syndrome (Business Wire) +7.97%
Jun-02-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.08%
May-12-26 04:25PM	Neurogene: Q1 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates (Business Wire)
06:00AM	Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy (Business Wire)
May-06-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.71%
Apr-28-26 07:30AM	Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy (Business Wire)
Apr-20-26 07:30AM	Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors (Business Wire)
Apr-08-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-24-26 07:46AM	Neurogene: Q4 Earnings Snapshot (Associated Press Finance) +7.95%
07:30AM	Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates (Business Wire)
Mar-11-26 07:30AM	Neurogene to Participate in Stifel 2026 Virtual CNS Forum (Business Wire)
Mar-03-26 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.03% +8.73%
Feb-27-26 09:50AM	Block upgraded, Duolingo downgraded: Wall Street's top analyst calls (The Fly) +19.36%
08:06AM	Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy (Benzinga)
07:59AM	Here Are Fridays Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More (24/7 Wall St.)
07:40AM	Why Did NGNE Stock Surge 25% In Pre-Market Today? (New feeds test provider finance)
Feb-26-26 04:01PM	Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
09:05AM	Loading…
Feb-14-26 09:05AM	Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit (MarketBeat)
Feb-05-26 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Feb-04-26 04:01PM	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-26 07:00AM	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome (Business Wire)
Jan-05-26 07:30AM	Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -8.58%
Dec-04-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.17%
Nov-13-25 05:21PM	Neurogene: Q3 Earnings Snapshot (Associated Press Finance) -14.77% -14.04%
05:10PM	Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
Nov-12-25 04:01PM	Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome (Business Wire)
Nov-06-25 07:30AM	Neurogene Announces First Participant Dosed in Embolden Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Nov-05-25 04:01PM	Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.83%
Oct-09-25 07:00AM	Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden Registrational Trial in Q4 2025 (Business Wire) +22.18%
Oct-08-25 07:30AM	Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference (Business Wire) +10.06%
Oct-03-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.48%
Sep-05-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-20-25 11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com)
Aug-11-25 05:55PM	Neurogene: Q2 Earnings Snapshot (Associated Press Finance) -5.55%
04:10PM	Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
Aug-08-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:01PM	Neurogene Announces Registrational Trial Design for Embolden Study of NGN-401 Gene Therapy for Rett Syndrome (Business Wire) -7.49% +28.36%
Jun-18-25 09:16AM	Craig-Hallum bullish on Neurogene, initiates with a Buy (TipRanks)
Jun-06-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.80%
May-26-25 11:15AM	Short Report: Bears bite into Krispy Kreme after another weak earnings report (TipRanks)
May-16-25 07:00AM	Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV (Business Wire) -7.12%
May-09-25 07:30AM	Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates (Business Wire)
May-08-25 04:01PM	Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.23%
Apr-28-25 05:00PM	Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting (Business Wire) -5.91% -10.14%
Apr-02-25 04:01PM	Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome (Business Wire) +8.34% -7.55%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -17.55%
Mar-24-25 04:10PM	Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates (Business Wire)
Feb-24-25 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
Nov-18-24 05:25PM	Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire) -42.58% -13.07%
04:14PM	How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week (Investor's Business Daily)
09:48AM	Neurogene Down 36% Extends Losses After Side Effect Derails Its Rett Syndrome Drug (Investor's Business Daily)
06:45AM	Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
Nov-12-24 04:10PM	Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal (Investor's Business Daily) -44.08%
10:18AM	Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect (Investor's Business Daily)
06:58AM	Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data (GuruFocus.com)
Nov-11-24 04:01PM	Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
Nov-05-24 07:54AM	Neurogene Secures $200M for Genetic Therapy Development (TipRanks)
Nov-04-24 07:30AM	Neurogene Announces Oversubscribed $200 Million Private Placement (Business Wire) +43.26%
Oct-21-24 07:30AM	Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Aug-09-24 02:52PM	NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 (InvestorPlace)
07:30AM	Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
Aug-07-24 07:30AM	Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome (Business Wire)
Jul-02-24 07:30AM	Neurogene to Participate in BMO Genetic Medicines Summit (Business Wire) -5.32%
Jul-01-24 07:30AM	Neurogene Announces Addition to Russell 3000 Index (Business Wire) +11.62%
Jun-19-24 09:23AM	Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation (Insider Monkey)
Jun-18-24 09:26AM	Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire) -24.20%
Jun-05-24 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
Jun-03-24 07:30AM	Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program (Business Wire)
May-10-24 01:54PM	NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
May-07-24 06:19AM	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting (Business Wire)
Apr-22-24 04:36PM	Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM	Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-18-24 04:14PM	Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire) +20.00%
Mar-04-24 07:30AM	Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
Feb-29-24 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM	Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
Jan-05-24 07:00AM	Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
Dec-19-23 07:00AM	Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McMinn Rachel	Chief Executive Officer	Sep 22 '26	Option Exercise	25.32	756	19,142	1,345,063	Oct 02 02:49 PM
Cvijic Christine Mikail	President and CFO	Jul 07 '26	Sale	36.13	4,200	151,763	84,040	Jul 07 09:08 PM
Cvijic Christine Mikail	President and CFO	Jul 06 '26	Sale	36.02	600	21,613	88,240	Jul 07 09:08 PM
Cvijic Christine Mikail	President and CFO	Jul 02 '26	Sale	34.82	4,061	141,417	88,840	Jul 02 06:42 PM
Cvijic Christine Mikail	President and CFO	Jul 01 '26	Sale	34.06	739	25,170	92,901	Jul 02 06:42 PM
Cvijic Christine Mikail	President and CFO	May 06 '26	Sale	31.25	9,600	300,043	93,640	May 08 11:51 AM
Christine Cvijic	Officer	May 06 '26	Proposed Sale	28.94	14,400	416,736		May 06 04:14 PM
Cvijic Christine Mikail	President and CFO	Mar 26 '26	Sale	21.62	2,558	55,316	103,240	Mar 30 05:38 PM
McMinn Rachel	Chief Executive Officer	Mar 26 '26	Sale	22.07	3,352	73,995	1,344,307	Mar 30 05:38 PM
Jordan Julie	Chief Medical Officer	Mar 26 '26	Sale	21.89	828	18,128	12,472	Mar 30 05:38 PM
Cobb Stuart	Chief Scientific Officer	Mar 13 '26	Sale	20.81	6,797	141,446	30,497	Mar 17 06:01 PM
Cvijic Christine Mikail	President and CFO	Mar 13 '26	Sale	20.81	4,045	84,176	105,798	Mar 17 06:01 PM
STUART COBB	Officer	Mar 13 '26	Proposed Sale	22.30	6,797	151,573		Mar 13 04:20 PM
Cvijic Christine Mikail	President and CFO	Feb 27 '26	Sale	25.11	4,800	120,526	109,843	Mar 03 05:03 PM
Christine Cvijic	Officer	Feb 27 '26	Proposed Sale	19.68	9,600	188,928		Feb 27 04:51 PM

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

FounderDr. Rachel L. McMinn Ph.D.

PresidentMs. Christine Mikail Cvijic J.D.

Chief Medical OfficerDr. Julie Jordan M.D.

Chief Scientific OfficerDr. Stuart Cobb Ph.D.

Executive Director of Investor RelationsMs. Lina Li

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGNE

Neurogene Inc

Upgrade your Finviz experience